Walvax

The state of the fight: 

A slew of vaccine manufacturers announced plans to tackle the Omicron variant.
  Aspen Pharmacare and J&J neared a deal that would let the South African manufacturer market its own version of the Janssen shot.
  Gavi’s board approved the alliance’s COVAX strategy for 2022.

AUTHORIZED VACCINES  


New research on the Pfizer/BioNTech shot affirmed its efficacy in younger people and its safety in older people.
 

The state of the fight: 

More European countries cautioned against Moderna’s vaccine for younger people over concerns about side effects.
  Generics companies are preparing to roll out their versions of Merck’s molnupiravir oral antiviral.
  Pfizer is in talks with 90 countries over supply deals for its antiviral candidate.

 

AUTHORIZED VACCINES  


France and Germany recommended against the Moderna vaccine for people under 30 over concerns about…

The state of the fight: 

A U.S. regulatory committee endorsed booster doses for vulnerable people and those over age 65.
  Kenya outlined plans to start fill-finish production of Covid-19 shots in early 2022.
  An SII subsidiary scooped up a 15% stake in Biocon’s biologics unit as the companies launched a strategic alliance to produce and commercialize vaccines. Approved or authorized vaccines

 
A new substudy in The Lancet supports flexible schedules for the…

The state of the fight: 

The U.S. FDA set a September date to discuss Pfizer/BioNTech boosters while E.U. officials saw “no urgent need” for boosters in the already vaccinated.
  Recruitment started in India for a late-stage trial of Serum Institute of India’s Covovax in children, and Biological E won approval to study its Corbevax in children.
  Prehospital antiplatelet therapy (such as aspirin) was associated with significantly lower in-hospital mortality in some…

The state of the fight: 

Zydus Cadila’s three-dose, needle-free ZyCoV-D became the first authorized DNA-based Covid-19 vaccine.
  AstraZeneca’s AZD7442 long-acting antibody reduced infection risk by 77% in Phase 3.
  PAHO’s Revolving Fund will begin procuring Covid-19 vaccines for member states. Approved or authorized vaccines

 
Assessing antibody levels to predict Moderna’s effectiveness: Researchers at Seattle’s Fred Hutchinson Cancer Research Center announced…

Maryland-based Sirnaomics announced last week that it will partner with China’s Walvax to co-develop its STP702 RNA interference-based influenza A therapy candidate.
 
Walvax will shell out $6.4 million upfront (plus additional milestone payments) for exclusive development and commercialization rights for STP702 in territories including China, Hong Kong, Macao and Taiwan, the press release said.

Mentions:

The state of the hunt:

The AstraZeneca/Oxford vaccine secured its first authorizations.
  Novavax launched a 30,000-participant North American Phase 3 trial for its recombinant vaccine.
  CNBG claimed 79% efficacy for the inactivated jab from its Beijing subsidiary but provided scant data.

 

Vaccines


Approved or authorized vaccines
 
UK authorizes AstraZeneca/Oxford jab: Britain’s Medicines and Healthcare products Regulatory Agency…

The state of the hunt:

The Pfizer/BioNTech vaccine received several new authorizations, including from the European Union.
  Canada joined the U.S. in authorizing Moderna’s jab. .
  Argentina and Belarus became the first countries outside Russia to OK Sputnik V.

 

Vaccines


Approved or authorized vaccines
 
Pfizer and BioNTech will market their BNT162b2 vaccine in the European Union under the brand name Comirnaty after receiving…

Beijing-based Sinovac announced last week that the China National Medical Products Administration has approved its 23-valent pneumococcal polysaccharide (PPSV23) shot—the company’s first bacterial vaccine licensure, according to the press release.

According to lot release data, Sinovac will compete for PPSV23 market share in China against Beijing Minhai, Chengdu Institute of Biological Products, Merck and Walvax.

In other Chinese vaccine news, Shenzhen Kangtai (BioKangtai)…

The state of the hunt:

Serum Institute of India is reportedly pursuing up to $1 billion in private equity funding for its Covid-19 vaccine projects.
  J&J plans 60,000-participant Phase 3 trials of its Janssen subsidiary’s vaccine candidate.
  Roche will help develop and manufacture Regeneron’s REGN-COV2 antibody cocktail, more than tripling production capacity of the drug.

 

Vaccines

Phase 3 trials:
 
Brazil approved Phase 3 trials of…